Roth thinks Capricor Therapeutics drug could still be approved by August 31

Following news that the FDA had withdrawn it notice for the Cellular, Tissue, and Gene Therapies Advisory Committee meeting tentatively scheduled for July 30 to discuss the potential path forward for Capricor’s deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, Roth Capital notes shares are down about 11% today on the news. The firm, which speculates that a new Ad Comm may be forthcoming, possibly in early August, thinks the drug could still be approved by August 31, the analyst tells investors. Roth has a Buy rating and $31 price target on Capricor Therapeutics (CAPR) shares.